Cite

HARVARD Citation

    Powles, T. et al. (n.d.). Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record